MRI links hearing loss to increased dementia risk
MRI has shown that hearing loss may increase dementia risk in seniors not yet cognitively impaired in ways distinct from those that tend to be associated with conditions such as Alzheimer's and cerebrovascular disease.A team led by Thomas Parker, MD, of the Imperial College London in the U.K. found that, compared with older adults who did not have hearing impairment, those who did had faster rates of whole brain atrophy. The findings were published April 3 in the Journal of Neurology, Neurosurgery and Psychiatry."Our data suggest a complex interplay of hearing ability, neurodegeneration, and cognition and implicate pathway...
Source: AuntMinnie.com Headlines - April 10, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Subspecialties Neuroradiology Source Type: news
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet said implementation will require careful consideration of the technology’s benefits and detriments, according to an article published April 6 in Radiography.
Lead author Geoff Currie, PhD, of Charles Sturt University in New South Wales, Australia, and U.S. colleagues, discussed the potential for AI across what they describe as the “five pillars” of sustainability in nuclear medicine (social, human, economic, ecological, and environmental) and noted its benefits and threats in each pillar.
“AI, digital twins, an...
Source: AuntMinnie.com Headlines - April 9, 2024 Category: Radiology Tags: Nuclear Medicine Artificial Intelligence Source Type: news
Suicide overtakes dementia to become eighth leading cause of death in men: New CDC data reveals America's biggest killers
The CDC found suicide was the eighth leading cause of death in men in 2021, with 38,400 deaths per year, while Alzheimer's was ninth at 37,000 fatalities. (Source: the Mail online | Health)
Source: the Mail online | Health - April 8, 2024 Category: Consumer Health News Source Type: news
Botulism After 'Botox'? NEJM Ignored Nazi Atrocities; Jungle Jack's Alzheimer's
(MedPage Today) -- Note that some links may require registration or subscription.
The Tennessee Department of Health said it's collaborating with the CDC and FDA to investigate botulism-like symptoms in people who received Botox-like botulinum... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 8, 2024 Category: Psychiatry Source Type: news
Comparing survival rates and mortality in operative versus nonoperative treatment for femoral neck fractures among Alzheimer's disease patients: a retrospective cohort study - Yang Y, Drake SA, Wang J, Shen GC, Miao H, Morgan RO, Du XL, Lairson DR.
INTRODUCTION: Addressing femoral neck fractures resulting from ground-level falls in older adults with Alzheimer's disease (AD) involves a personalized treatment plan. There is considerable ongoing debate concerning the relative advantages and disadvantage... (Source: SafetyLit)
Source: SafetyLit - April 8, 2024 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
After life-changing losses, these millennials are now trying to help others preserve their loved ones' legacy
It wasn't until he became a father that Nicholas Worley rekindled the idea of preserving memories of his loved ones and their legacies. That idea first germinated when Worley was just 16. He lost his paternal grandfather to prostate cancer and his maternal grandmother to Alzheimer's that same year…#nicholasworley #britishcolombian #inalife #hongkong #singaporean #hareshtilani #terencechia #whartonschool #singapore #singaporeans (Source: Reuters: Health)
Source: Reuters: Health - April 7, 2024 Category: Consumer Health News Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Distance to Neurologist, PCP May Explain Alzheimer Disease Disparities
FRIDAY, April 5, 2024 -- Distance to a neurologist and primary care physician may explain some of the disparities in Alzheimer disease and related dementia (AD/ADRD) outcomes, according to a study published online March 20 in Alzheimer ' s&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 5, 2024 Category: Pharmaceuticals Source Type: news
COVID-19 ‘Radically’ Changed the Leading Causes of Death
COVID-19 became the second leading cause of death globally in the year after it was declared a pandemic, according to a study published in the Lancet.
While heart disease remained the top killer, COVID “radically altered” the main five causes of death for the first time in 30 years, displacing stroke, the publication said. In 2021, 94 in every 100,000 people died from COVID, on an age-standardized basis.
Since 1990, global life expectancy increased by 6.2 years, mainly due to reductions in death from diarrhea and lower respiratory infections and better outcomes for people suffering from a stroke or ischem...
Source: TIME: Health - April 5, 2024 Category: Consumer Health News Authors: Alex Tanzi/Bloomberg Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio
Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq (florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S. for the detection of beta-amyloid plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline, according to the vendor. Neuraceq may also assist in assessing treatment eligibility for newly approved anti-amyloid drugs or for enrollment in clinical tri...
Source: AuntMinnie.com Headlines - April 5, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Nuclear Radiology Molecular Imaging Industry News Source Type: news
Would YOU want to know you've got Alzheimer's? Warning that NHS trial of blood tests to improve 'shocking' diagnosis rates may WRONGLY tell patients they have incurable disease
In efforts to revolutionise 'shocking' diagnostic rates, thousands of Brits will have their blood tested for signs of the memory-robbing illness. (Source: the Mail online | Health)
Source: the Mail online | Health - April 4, 2024 Category: Consumer Health News Source Type: news
Thousands of Britons to receive cheap blood tests for Alzheimer's in landmark trials to improve 'shocking' NHS diagnosis rates
Researchers from Oxford and University College London , will use the cheap tests to detect proteins in the blood linked to the disease and other forms of dementia. (Source: the Mail online | Health)
Source: the Mail online | Health - April 4, 2024 Category: Consumer Health News Source Type: news
Thousands to be offered blood tests for dementia in UK trial
More than 50 clinics will offer tests to about 5,000 people who are worried about their memory in five-year trialThousands of people across the UK who are worried about their memory will receive blood tests for dementia in two trials that doctors hope will help to revolutionise the low diagnosis rate.Teams from the University of Oxford and University College London will lead the trials to research the use of cheap and simple tests to detect proteins for people with early stages of dementia or problems with cognition, with the hope of speeding up diagnosis and reaching more people.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 4, 2024 Category: Science Authors: Mabel Banfield-Nwachi Tags: Dementia Alzheimer's Medical research Society Science Mental health Neuroscience UK news Source Type: news
French-led team unveils 11.7 tesla MRI scans of human brain
A research group based in Saclay, near Paris, has taken the wraps off what it claims are the world's first MRI scans of the human brain in vivo taken at a field strength of 11.7 tesla. President Emmanuel Macron has congratulated the researchers on social media.
"The first images surpassed our expectations, giving after just four minutes, mind-blowing brain images without any artifacts, with superb tissue contrast and resolution, which represents a volume equivalent to a few thousand neurons," Denis Le Bihan, PhD, founding director of the NeuroSpin research facility and founder of Iseult Project of the French Alternative E...
Source: AuntMinnie.com Headlines - April 4, 2024 Category: Radiology Authors: Philip Ward Tags: MRI Source Type: news
Trial of blood tests to spot Alzheimer's sooner
The long-term hope is that more people will be able to access new treatments at an earlier stage. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 4, 2024 Category: Consumer Health News Source Type: news
